据外电综合报道：
NEW YORK--(Business Wire)--
Pfizer Inc said today that the Court of Appeal of Barcelona has
upheld the company's enantiomer patent covering the calcium salt of
atorvastatin, the active ingredient in Lipitor, reversing the lower
court decision. The enantiomer patent expires in July 2010.
The patent was challenged jointly by generic companies
Laboratorios Cinfa S.A., Kern Pharma S.L., Laboratorios Alter S.A. and
Laboratorios Belmac S.A., and is one of four separate challenges to
the enantiomer patent by generic companies in Spain. Lipitor is sold
in Spain under the brand names Zarator and Cardyl. "This is a victory
not only for Pfizer, but for all innovators pursuing high-risk medical
discoveries and for the patients who benefit from those discoveries,"
said Pfizer Senior Vice President and Associate General Counsel Peter
C. Richardson. Cinfa, Kern, Alter and Belmac can seek to appeal the
decision to the Supreme Court of Spain.
Pfizer Inc
Vanessa Aristide, 212-733-3784
Copyright Business Wire 2008
·[股票大盘] 走势预测：下周一大盘是涨还是跌？
·[股市实战] 股票可以改变女人的十件事（经典）
·[超级散户] 老股民炒股15年悟出9个字的炒股经验
·[内幕传闻] 爆料：侯宁炒股比散户赔得还惨！
·[超级股民] 老股民谈特殊时期的操盘思路
·[黑马奔腾] 基金曝光鲜为人知操盘内幕
·[谈股论金] 55岁男子震中逃生后首先问股市行情
·[基金理财] 一位四川股民走了他买的股票怎么办？
上 证
深 成
中小板
新闻排行
股票
基金
个股
财经
| 关于腾讯 | About Tencent | 服务条款 | 广告服务 | 腾讯招聘 | 腾讯公益 | 客服中心 | 网站导航 |
Copyright © 1998 - 2009 Tencent. All Rights Reserved  |
| 腾讯公司 版权所有 |
